Integra to test nerve regeneration product:
This article was originally published in Clinica
Executive Summary
Integra LifeSciences plans to begin Phase II clinical trials of its product for peripheral nerve regeneration in September. Consisting of a bioresorbable collagen tube which is sutured to each end of the severed nerve bundle, the device gives the nerves a protective environment and a direction in which to grow. The Plainsboro, New Jersey-based company said that compared with current microsurgical methods its regeneration device offered rapid closure techniques for peripheral nerve repair with fewer scars.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.